EGFR and glioblastoma: Since EGFR amplification or activating mutations are present in up to 57% of GBMs (An et al., 2018), and since SRC phosphorylation can be detected as early as 6 h after exposure of GBM cells to ispinesib, development of STAT3-mediated resistance could develop rapidly.